Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
Iveric rockets on mid-stage trial of Zimura in dry AMDShares in US biotech Iveric Bio have shot up after the company said its lead drug Zimura had Share XIveric rockets on mid-stage trial of Zimura in dry AMDhttps://pharmaphorum.com/news/iveric-rockets-on-mid-stage-trial-of-zimura-in-dry-amd/
Novartis backs brolucizumab with new head-to-head Eylea trialNovartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Share XNovartis backs brolucizumab with new head-to-head Eylea trialhttps://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
Regeneron to develop long release Eylea successorRegeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation Share XRegeneron to develop long release Eylea successorhttps://pharmaphorum.com/news/regeneron-looks-sustained-release-eye-drug/